%0 Journal Article
%T Clinical and virological features of chronic hepatitis B in the French national surveillance program, 2008-2012: A cross-sectional study.
%A Chevaliez S
%A Roudot-Thoraval F
%A Brouard C
%A Gordien E
%A Zoulim F
%A Brichler S
%A Brodard V
%A Pioche C
%A Pawlotsky JM
%A Leroy V
%A  
%A Chevaliez S
%A Roudot-Thoraval F
%A Brouard C
%A Gordien E
%A Zoulim F
%A Brichler S
%A Brodard V
%A Pioche C
%A Pawlotsky JM
%A Leroy V
%A  
%J JHEP Rep
%V 4
%N 12
%D Dec 2022
%M 36313185
%F 9.917
%R 10.1016/j.jhepr.2022.100593
%X <B>UNASSIGNED: </B>Among people living with HBV, only a subset of individuals with chronic hepatitis is in need of treatment, and this proportion varies according to the population, region, and setting. No estimates of the proportion of people who are infected with HBV and meet the treatment eligibility criteria in France are available.<BR><B>UNASSIGNED: </B>552 treatment-naïve individuals with chronic HBV infection referred for the first time to a hepatology reference centre between 2008 and 2012 were prospectively included. Demographic, clinical, and laboratory data were analysed.<BR><B>UNASSIGNED: </B>In total, 61.1% of patients were males, with a median age of 37.5 years. Moreover, 64% were born in an intermediate- or high-HBV endemicity country, and 90% were HBeAg-negative. At referral, median HBV DNA and HBsAg levels were 3.3 and 3.6 log IU/ml, respectively; 37.8% of patients had alanine aminotransferase >40 U/L, and 29.0% had moderate or severe fibrosis (≥F2), including 9.4% with cirrhosis. The most prevalent genotypes were D (34.7%), E (27.4%), and A (25.7%). Coinfections were rare: 2.4% were HIV-positive, 4.0% were HCV-positive, and 6.0% were HDV-positive. According to the 2017 EASL Clinical Practice Guidelines, using a single time point analysis, 2.7% of patients were classified as HBeAg-positive chronic infection, 6.1% as HBeAg-positive chronic hepatitis B, 26.5% as HBeAg-negative chronic hepatitis B, and 61.1% as HBeAg-negative chronic infection, whereas 3.6% patients could not be classified. The performance of HBsAg level quantification to identify individuals with HBeAg-negative chronic hepatitis B was poor. A total of 29.1% met the criteria for initiation of antiviral treatment, whereas 66.5% remained under routine clinical surveillance. Most eligible patients initiated recommended first-line therapies, including tenofovir (45.3%), entecavir (36.8%), or pegylated interferon alpha (11.6%).<BR><B>UNASSIGNED: </B>Of all cases, 9.4% had cirrhosis at presentation and 29.1% met the 2017 EASL Clinical Practice Guidelines treatment criteria. HBsAg levels failed to accurately identify individuals with HBeAg-negative chronic infection.<BR><B>UNASSIGNED: </B>Among French adults chronically infected with HBV referred for the first time to hepatology reference centres, about one-third had a significant liver disease. Approximately one-third of individuals met criteria for initiation of antiviral treatment based on entecavir or tenofovir or, occasionally, pegylated interferon alpha.